Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer: A Prospective, Multi-Center, Randomized Phase III Non- Inferiority Trial (HUB Trial)

NCT07500701 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07500701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07500701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer: A Prospective, Multi-Center, Randomized Phase III Non- Inferiority Trial (HUB Trial)
Lead sponsor
Samsung Medical Center
Phase
Phase 3
Overall status
Recruiting
Start date
March 6, 2026
Completion date
December 31, 2034
Enrollment
270 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer